financial estimates
Oxford Nanopore Technologies Anticipates H1 Life Sciences Research Tools Revenue to Fall 2 Percent
The sequencing company estimates its life sciences research tools revenues will be about £84.0 million for the first half of 2024 versus £86.0 million in H1 2023.
MDxHealth Preliminary Q2 Revenues up 32 Percent
The company also raised its full-year 2024 guidance to up to $87 million, citing sales execution and operating discipline as drivers for its improved outlook.
QuidelOrtho Suspends Guidance After Lowering Full-Year Expectations on COVID, Savanna MDx Platform
Premium
The firm said it expects to reinstate guidance and reschedule its Investor Day at some point this year as new CEO Brian Blaser continues to assess the business.
Fulgent Genetics Core Q1 Revenues Grow 1 Percent
Core revenues, which exclude revenues from COVID-19 testing products and services, grew to $63.2 million, compared to $62.7 million a year ago for the El Monte, California-based laboratory services and drug development firm.
Pacific Biosciences Q4 Revenues More Than Double as Firm Lays off 6 Percent of Workforce
The company announced the layoffs, which affected about 50 employees, predominantly in R&D, during its fourth-quarter and 2023 earnings call.